+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset



De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset



Movement Disorders 13(2): 234-241



In contrast to levodopa (L-dopa), de novo administration of the D2-like receptor agonist bromocriptine to patients with Parkinson's disease (PD) or to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated subhuman primates is not associated with the onset of significant dyskinesia. We now compare the ability of the novel D2-like selective dopamine agonist ropinirole with that of bromocriptine and L-dopa to induce dyskinesia in MPTP-treated common marmosets. MPTP-treated common marmosets were treated with placebo, L-dopa plus carbidopa, ropinirole, or bromocriptine daily for 30 days (n = 4 per group) in doses that were titrated to similarly increase locomotion and improve motor disability. L-dopa rapidly induced dyskinesia of moderate to severe intensity, whereas ropinirole and bromocriptine produced mild dyskinesia over the course of the study that was significantly less severe than in the L-dopa-treated group (p < 0.05). However, in a separate group of marmosets previously primed with L-dopa to exhibit dyskinesia, ropinirole administration elicited severe dyskinesias comparable with that of L-dopa in a dose-dependent fashion. Ropinirole, in common with bromocriptine, has a lesser tendency than L-dopa to produce dyskinesia while similarly improving motor performance in drug-naive MPTP-treated marmosets. However, in common with other dopamine agonists, ropinirole will elicit comparable dyskinesia once L-dopa priming has occurred. These results predict a similar response to ropinirole and other long-acting dopamine agonists in L-dopa-naive patients with PD and emphasize the importance of avoiding initial dyskinesia induction through early use of dopamine agonist drugs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045706868

Download citation: RISBibTeXText

PMID: 9539335

DOI: 10.1002/mds.870130207


Related references

Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets. Neuroscience 115(4): 1047-1058, 16 December, 2002

Differential effects of ropinirole, bromocriptine and L-DOPA on striatal preprodynorphin mRNA expression in the MPTP-treated marmoset. British Journal of Pharmacology 128(PROC Suppl. ): 282P, 1999

A comparison of ropinirole, L-dopa, and bromocriptine treatment on the development of dyskinesia in MPTP-treated common marmosets. Neurology 48(3 Suppl. 2): A119, 1997

The ability of ropinirole to reverse L-dopa-induces dyskinesia in MPTP-treated marmosets. European Journal of Neurology 10(Suppl. 1): 19, 2003

Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Movement Disorders 18(11): 1301-1305, 2003

Chronic L-DOPA administration induces dyskinesias in the MPTP-treated marmoset. British Journal of Pharmacology 112(PROC Suppl. MAY): 150P, 1994

Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Experimental Neurology 204(1): 162-170, 2007

Effects of repeated treatment with L-DOPA, bromocriptine and ropinirole in drug naive MPTP-treated common marmosets. British Journal of Pharmacology 118(PROC Suppl. JULY): 37P, 1996

Changes in striatal preproenkephalin A and preprotachykinin mRNA expression The effect of L-dopa, bromocriptine, and ropinirole in MPTP-treated marmosets. Neurology 50(4 Suppl. 4): A135, 1998

Effects of repeated treatment with combinations of L-DOPA and ropinirole on dyskinesia induction in MPTP-treated common marmosets. British Journal of Pharmacology 123(PROC Suppl. ): 252P, 1998

Inducing dyskinesia in MPTP-treated common marmosets The effects of repeated treatment with combinations of L-dopa and ropinirole. Neurology 50(4 Suppl. 4): A135, 1998

Differential effects of ropinirole, bromocriptine and L-DOPA on striatal dopamine D-2 receptor binding in MPTP-treated common marmosets. British Journal of Pharmacology 122(PROC Suppl. ): 315P, 1997

Ropinirole, bromocriptine and L-DOPA have a differential effect on striatal dopamine D-2 and D-3 but not D-1 receptor mRNA expression in MPTP-treated marmosets. British Journal of Pharmacology 136(Proceedings Suppl.): 68P, 2002

Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation. Movement Disorders 17(5): 887-901, 2002